logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Marina Chiara Garassino

University of Chicago Medicine
H指数:73
被引数:4.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy

SUNRAY-02：奥莫罗西比与免疫疗法联合治疗经根治性治疗后处于II-III期KRAS G12C突变型非小细胞肺癌的研究

Future Oncology
IF2.6
2026-10-010
OA
Jamie Chaft; Jay M. Lee; Suresh Senan; Joel W. Neal; Ernest Nadal; Marcelo V. Negrao; Sanjay Popat; Marina C. Garassino; Jhanelle E. Gray; Se-Hoon Lee; Julien Mazieres; Michael Thomas; Martin Benes; Hui Liu; Jian Liu; Qinli Lily Ma; Grace Segall; Tarun Puri; Yi-Long Wu
Leave No Data Behind: Exploring a new paradigm in oncology with foundation models and large language models

不留数据：探索基于基础模型和大型语言模型的肿瘤学新范式

Cell Reports Medicine
IF10.6
2026-08-040
OAAI
Federica Corso; Aleksandra Zec; Margherita Favali; Marta Ligero; Lars Hilgers; Luca Mauro Invernizzi; Laura Mazzeo; Adria Marcos Morales; Gustav Anton Müller-Franzes; Ines Prata Machado; Felix Busch; Vanja Mišković; Francesco Trovò; Claudia Proto; Giuseppe Lo Russo; Mario Occhipinti; Marta Brambilla; Teresa Beninato; Susan Halabi; Marina Chiara Garassino
Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology

重新定义胸腺上皮肿瘤的治疗前景：精准治疗、联合疗法及新兴生物学

npj Precision Oncology
IF8
2026-06-260
OAAI
Jennifer A. Marks; Rohan Maniar; Kavitha J. Ramchandran; Erica Pietroluongo; Mehmet Altan; Surbhi Singhal; Mihaela Aldea; Jonathan W. Goldman; Jonathan W. Reiss; Heather Wakelee; Patrick J. Loehrer; Marina Chiara Garassino; Anja C. Roden; Jordi Remon; Christopher S. Nabel; Chul Kim
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC

ENTRÉE 肺平台试验子研究1：法拉地利姆单抗联合多西他赛对比多西他赛单药治疗晚期/复发性NSCLC的II期随机疗效与安全性分析

Clinical Lung Cancer
IF3.3
2026-04-080
PRE
Marina Chiara Garassino; Sophie Cousin; Benjamin Besse; Adrian Sacher; Sergey Orlov; Michael Schenker; Enriqueta Felip; Oleg Gladkov; Cristina H. Messina; Antara Majumdar; Zhenhua Jeremy Wu; Natalie O. Karpinich; Steven Hirschfeld; Marc Ballas; Martin Reck
Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%

网络分析预测PD-L1<50%的晚期NSCLC对pembrolizumab的应答

Cancer Cell International
IF6
2026-03-260
OA
Mario Occhipinti; Antonella Cruoglio; Silvia Marchesi; Arsela Prelaj; Marco Petrilli; Aurelia Rughetti; Paolo Ambrosini; Elisabetta Ferretti; Claudia Proto; Monica Ganzinelli; Marta Brambilla; Laura Mazzeo; Teresa Beninato; Filippo de Braud; Marina Chiara Garassino; Lorenzo Farina; Giuseppe Lo Russo; Manuela Petti
Probing Cellular Activity Via Charge-Sensitive Quantum Nanoprobes

通过电荷敏感的量子纳米探针探测细胞活性

Advanced Materials
IF26.8
2026-02-040
OAAI
Uri Zvi; Shivam Mundhra; David Ovetsky; Qing Chen; Aidan R. Jones; Stella Wang; Maria J. Román-Vazquez; Marie Kim; Udoka M. Ibeh; Michele Ferro; Kunle Odunsi; Marina C. Garassino; Michael E. Flatté; Melody A. Swartz; Denis R. Candido; Aaron Esser-Kahn; Peter C. Maurer
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

晚期非小细胞肺癌患者接受双重CTLA-4和PD-L1或PD-1阻断治疗及生物标志物基础亚组分析的长期总生存：一项系统评价和重建个体患者数据荟萃分析

The Lancet Oncology
IF0
2025-09-290
PRE
Alessandro Di Federico; Sara Stumpo; Francesco Mantuano; Andrea De Giglio; Francesca Lo Bianco; Federica Pecci; Joao V Alessi; Xinan Wang; Francesca Sperandi; Barbara Melotti; Francesco Gelsomino; Ferdinandos Skoulidis; Marina C Garassino; Solange Peters; Mark M Awad; Andrea Ardizzoni; Biagio Ricciuti
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较（FRONT-BRAF）：一项多中心、回顾性队列研究

The Lancet Oncology
IF0
2025-09-290
PRE
Alessandro Di Federico; Kaiwen Wang; Monica F Chen; Adam A Barsouk; Arianna Pagliaro; Lanyi N Chen; Francesca R Ogliari; Paul Stockhammer; Rajat Thawani; Shahm Raslan; Eleonora Gariazzo; Francesca Fusco; Grace M Hambelton; Fabrizio Citarella; David Meyer; Mihaela Aldea; Andrea De Giglio; Joao V Alessi; Federica Pecci; Francesco Gelsomino; Marcelo Corassa; Natalie I Vokes; Xinan Wang; Dario de Biase; Fawzi Abu Rous; Phurin Areesawangkit; Omar Elghawy; Alessio Cortellini; Giulio Metro; Roberto Ferrara; Mark M Awad; Aliyah Pabani; Joseph C Murray; Federico Cappuzzo; Marina C Garassino; Ibiayi Dagogo-Jack; Gregory Riely; Michael Grant; Benjamin O Herzberg; Andrea Ardizzoni; David Planchard; Bruce E Johnson; Corey J Langer; Michael Offin; Marcelo V Negrao; Biagio Ricciuti
Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study

度伐利尤单抗联合铂类-依托泊苷治疗广泛期小细胞肺癌：CASPIAN III期研究中不同年龄、性别和铂类亚组的结果

Clinical Lung Cancer
IF3.3
2025-08-050
OAAI
Niels Reinmuth; Jonathan W. Goldman; Yuanbin Chen; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Marina Chiara Garassino; Artem Poltoratskiy; Francesco Verderame; Libor Havel; Igor Bondarenko; György Losonczy; Nikolay Conev; Shannon Kummer; Helen Mann; Priti Chugh; Tapashi Dalvi; Luis Paz-Ares
THE ITALIAN MAURIS PHASE IIIB TRIAL OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH NEWLY DIAGNOSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER: 3-YEAR END-OF-STUDY RESULTS

意大利MAURIS 3期B研究：阿替利珠单抗联合卡铂和依托泊苷治疗新诊断广泛期小细胞肺癌的3年研究结束结果

Clinical Lung Cancer
IF3.3
2025-07-090
OAAI
Floriana Morgillo; Ester Del Signore; Emilio Bria; Filippo de Marinis; Fortunato Ciardiello; Marina Chiara Garassino; Alessio Stefani; Francesco Verderame; Alessandro Morabito; Andrea Sbrana; Giuseppe Tonini; Marina Gilli; Rossana Berardi; Paola Adriana Taveggia; Alessandra Bearz; Angelo Delmonte; Maria Rita Migliorino; Cesare Gridelli; Giovanni Maria Fadda; Manuela Iero; Andrea Ardizzoni
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer

接受帕博利珠单抗联合化疗作为非小细胞肺癌一线治疗的患者中，肿瘤应答和应答持续时间对生存的影响

Oncology and Therapy
IF3.2
2025-06-110
OA
Marina C. Garassino; Ying Cheng; Delvys Rodriguez-Abreu; Silvia Novello; Julien Mazieres; Andrew G. Robinson; Steven F. Powell; Balazs Halmos; Jhanelle E. Gray; Meihua Wang; Cong Chen; Jing Yang; Fabricio Souza; Paul Schwarzenberger; Luis Paz-Ares
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial

度伐利尤单抗在不可切除的III期非小细胞肺癌患者序贯化放疗后的应用——来自PACIFIC-6 II期试验的最终分析

ESMO Open
IF8.3
2025-06-010
OA
M.C. Garassino; J. Khalifa; M. Reck; C. Chouaid; H. Bischoff; N. Reinmuth; L. Cove-Smith; T. Mansy; D.L. Cortinovis; M.R. Migliorino; A. Delmonte; J. Garcia Sánchez; L.E. Chara Velarde; R. Bernabe; L. Paz-Ares; P. Chander; I. Diaz Perez; K. Foroutanpour; U. Emeribe; C. Faivre-Finn
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis

新辅助与围手术期化免疫疗法根据病理反应在可切除非小细胞肺癌中的比较：一项重构的个体患者数据meta分析

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2025-06-011
PRE
Nuccio, Antonio; Salomone, Fabio; Servetto, Alberto; Ricciuti, Biagio; Marinelli, Daniele; Bulotta, Alessandra; Veronesi, Giulia; Garassino, Marina Chiara; Torri, Valter; Besse, Benjamin; Viscardi, Giuseppe; Ferrara, Roberto
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Cemiplimab单药治疗PD-L1表达≥50%的晚期NSCLC患者的一线治疗：EMPOWER-Lung 1研究五年结局

Journal of Thoracic Oncology
IF20.8
2025-03-190
OAAI
Saadettin Kilickap; Ana Baramidze; Ahmet Sezer; Mustafa Özgüroğlu; Mahmut Gumus; Igor Bondarenko; Miranda Gogishvili; Marina Nechaeva; Michael Schenker; Irfan Cicin; Ho Gwo Fuang; Yaroslav Kulyaba; Kasimova Zyuhal; Roxana-Ioana Scheusan; Marina Chiara Garassino; Yuntong Li; Cong Zhu; Manika Kaul; Javier Perez; Frank Seebach; Heather Magnan

研究方向

暂未获取到该数据
M
Monica Ganzinelli
H 指数:31论文数:221被引数:3,591
C
Claudia Proto
H 指数:31论文数:300被引数:4,062
G
Giuseppe Lo Russo
H 指数:37论文数:335被引数:4,843
D
Diego Signorelli
H 指数:37论文数:223被引数:4,513
F
Filippo de Braud
H 指数:103论文数:1,561被引数:5.3万
M
Massimo Broggini
H 指数:53论文数:420被引数:9,690
G
Giulia Galli
H 指数:30论文数:198被引数:3,009
R
Roberto Ferrara
H 指数:44论文数:308被引数:1.0万
M
Mirko Marabese
H 指数:27论文数:96被引数:2,354
A
Arsela Prelaj
H 指数:26论文数:190被引数:2,689